NVision Quantum Technologies GmbH announced $55 million in Series B investment, sensing a significant change in biotechnology and testing. This funding round, led by the Abbott, marks the company’s ambitious expansion from its established roots in quantum sensing into the frontier of quantum computing. NVision is building what its leadership describes as an end-to-end, quantum-based platform designed to accelerate the discovery, design, and real-world validation of new life-saving therapies.
You can also read Quantum Centric Supercomputing Breaks Protein model Records
A Unified “Compute and Validate” Strategy
The “compute and validate” strategic approach is the basis of NVision’s growth. The “translational gap” the long and often unsafe interval between inventing a drug and testing it in a living organism has afflicted the pharmaceutical business for generations. NVision has developed a new platform called PIQC (Photonic Integrated Quantum Circuits).
PIQC’s quantum computing capabilities will be used to design drug candidates for biological targets that were previously considered inaccessible to traditional computers. NVision’s current POLARIS platform, a quantum-enhanced MRI technology, offers the ability to quickly validate such medications in an actual biological setting once a hypothesis has been developed. Researchers are able to reduce the gap between digital design and physical reality at a rate never seen before with this solid methodology.
You can also read Quantum Rabi Model: New Analytical Key to Two-Qutrit Systems
POLARIS: Redefining Medical Diagnostics Today
The company’s success is based on the demonstrated effectiveness of POLARIS, even though quantum computing is its next horizon. This quantum-enhanced sensing platform is already transforming how they understand disease biology. POLARIS makes it possible to evaluate metabolism in real time on standard MRI systems already present in hospitals by utilizing quantum technology to increase the MRI signals of sugar-based imaging agents by numerous orders of magnitude.
This is important because most imaging methods use morphology, which can take months to show size or form changes. On the other hand, metabolic changes happen extremely instantly. Within hours or days, medical professionals and researchers can evaluate a patient’s reaction to treatment using POLARIS.
The effects of this technology are already being felt. Renowned organizations including the Technical University of Munich in Germany, the University of Cambridge in the United Kingdom, and the Memorial Sloan Kettering Cancer Center in the United States are now installing POLARIS systems. NVision anticipates using about 20 centers throughout the United States, Europe, and Asia by the end of 2026. Notably, these systems don’t require the specific quantum knowledge usually associated with such complex physics to function in regular healthcare settings.
You can also read Pasqal Thoughts 2026: Quantum Computing Enters Real-World
PIQC: A New Class of Organic Qubits
The get into quantum computing was driven by a innovation discovery made during the development of POLARIS. NVision researchers identified a new class of organic molecule-based qubits. This discovery forms the foundation of PIQC (pronounced “Pixie”).
The PIQC architecture is built from first principles with a focus on scalability. Single-photon-emitting organic molecules, unlike “legacy” qubit approaches used by other quantum computing businesses, comprise its core. These organic qubits are directly incorporated into photonic chips as a thin layer. NVision has developed a scalable route toward the development of potent quantum computers that can be produced in large quantities by fusing this molecular layer with well-established photonic hardware and conventional semiconductor manufacturing processes.
Sella Brosh, CEO and co-founder of NVision, stated, “I see a future where quantum computers generate an explosion of drug hypotheses for diseases that are exceptionally difficult to treat today.” He underlined that POLARIS, which enables the “translational speed” required to obtain the advantages made in the computational phase, is the crucial second half of this goal.
You can also read Andrew Forbes Leads Quantum Leap to Fastest Internet
Strategic Investment and Global Recognition
The $55 million Series B round brings NVision’s total capital raised to $120 million. Abbott has early access to these new capabilities as the only strategic investor in the diagnostics sector, which enables the business to assess potential uses in disease detection, monitoring, and clinical decision-making. NVision’s capacity to “turn complex quantum science into scalable systems for real-world use” was commended by Peter Karabatsos, Divisional Vice President at Abbott.
The European Investment Bank (EIB), which offered a $17 million venture loan, also contributed significantly to the financing. According to Nicola Beer, Vice President of the EIB, NVision serves as an example of how innovative research can boost Europe’s innovation ecosystem while offering “concrete benefits for patients”. Playground Global, Matterwave/b2ventures, and Entrée Capital are additional investors. NVision is a “molecular spin-control powerhouse” that is part of the “tiny elite” of businesses who are currently effectively selling commercial quantum sensing technologies, according to Christian Reitberger of Matterwave Ventures.
Governmental policy provides additional support for this momentum. Quantum-Enhanced MRI (Q-MRI) is listed as a top objective for global leadership by 2030 in the European Commission’s recently published Quantum Europe Strategy. With its “Made in Europe” approach to global health, NVision’s POLARIS is positioned as a crucial guide for this approach. The business was also named a Top 10 Finalist for “The Spark: German Digital Award” in late 2025 in recognition of its creative use of quantum physics to address healthcare issues.
You can also read IONIX Chain Presale 2026: AI Meets Blockchain For Finance
In Conclusion
NVision aims to change the whole medical treatment lifecycle by combining the diagnostic accuracy of quantum sensing with the prediction capability of quantum computation. NVision is demonstrating that “quantum isn’t just about the future,” as noted by Ran Achituv of Entrée Capital.
You can also read Cleveland Clinic Quantum Innovation Catalyzer Program 2026
